News
Article
Author(s):
An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.
CONFERENCE REPORTER
Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.
Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.